Cargando…

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD

OBJECTIVE: To evaluate the safety of rituximab treatment before and during pregnancy in women with MS and neuromyelitis optica spectrum disorders (NMOSDs) who may be at risk of relapses by performing a systematic literature review combined with a retrospective single-center case series. METHODS: Stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Das, Gitanjali, Damotte, Vincent, Gelfand, Jeffrey M., Bevan, Carolyn, Cree, Bruce A.C., Do, Lynn, Green, Ari J., Hauser, Stephen L., Bove, Riley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858951/ https://www.ncbi.nlm.nih.gov/pubmed/29564373 http://dx.doi.org/10.1212/NXI.0000000000000453

Ejemplares similares

Clinic to in-home telemedicine reduces barriers to care for patients with MS or other neuroimmunologic conditions
por: Bove, Riley, et al.
Publicado: (2018)

Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
por: Esmaeili, Sara, et al.
Publicado: (2021)

pRNFL as a marker of disability worsening in the medium/long term in patients with MS
por: Cordano, Christian, et al.
Publicado: (2018)

Onset of secondary progressive MS after long‐term rituximab therapy – a case report
por: von Büdingen, H.‐Christian, et al.
Publicado: (2016)

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab
por: Kowarik, Markus C., et al.
Publicado: (2016)

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD
por: Cree, Bruce AC, et al.
Publicado: (2021)

Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children
por: Longoni, Giulia, et al.
Publicado: (2014)

Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2
por: Graf, Jonas, et al.
Publicado: (2020)

Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1
por: Graf, Jonas, et al.
Publicado: (2020)

COVID-19 in MS and NMOSD: A multicentric online national survey in Chile
por: Ciampi, Ethel, et al.
Publicado: (2020)

To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection
por: Stastna, Dominika, et al.
Publicado: (2022)

Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD
por: Kim, Sohyeon, et al.
Publicado: (2023)

CoachMS, an innovative closed-loop, interdisciplinary platform to monitor and proactively treat MS symptoms: A pilot study
por: Block, Valerie J, et al.
Publicado: (2021)

Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions
por: Krysko, Kristen M., et al.
Publicado: (2019)

Rituximab, MS, and pregnancy
por: Smith, Jessica B., et al.
Publicado: (2020)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

Reply to “Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS”
por: Bischof, Antje, et al.
Publicado: (2022)

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD
por: Shi, Mingchao, et al.
Publicado: (2022)

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

Experience of South American MS and/or NMOSD experts in practice during the COVID-19 pandemic: Focus on Telemedicine
por: Alonso, Ricardo, et al.
Publicado: (2021)

Lupus and NMOSD: The Blending of Humoral Autoimmunity
por: Ochi, Maria Goretti S., et al.
Publicado: (2020)

Epidemiology of Pediatric NMOSD in Germany and Austria
por: Lechner, Christian, et al.
Publicado: (2020)

Contemporary management challenges in seropositive NMOSD
por: Costello, Fiona, et al.
Publicado: (2022)

Differential Effects of MS Therapeutics on B Cells—Implications for Their Use and Failure in AQP4-Positive NMOSD Patients
por: Traub, Jan, et al.
Publicado: (2020)

Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS
por: Duan, Yunyun, et al.
Publicado: (2021)

Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey
por: Ricardo, Alonso, et al.
Publicado: (2020)

Plasmapheresis for NMOSD: Not a Rescue Therapy Anymore!?
por: Bhatia, Rohit, et al.
Publicado: (2019)

Plegia to walking: AHSCBMT in severe NMOSD relapse
por: Carlisle, Nicola, et al.
Publicado: (2020)

Therapy challenges for NMOSD in a patient with HIV
por: Engels, Daniel, et al.
Publicado: (2023)

Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic review
por: Mirmosayyeb, O., et al.
Publicado: (2023)

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD
por: Lin, Liuyu, et al.
Publicado: (2022)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
por: Fragoso, Diego Cardoso, et al.
Publicado: (2023)

Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis
por: Hyun, Jae-Won, et al.
Publicado: (2018)

Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD
por: Cook, Lawrence J., et al.
Publicado: (2019)

High-throughput investigation of molecular and cellular biomarkers in NMOSD
por: Yandamuri, Soumya S., et al.
Publicado: (2020)

Blood pressure and body fat percent in women with NMOSD
por: Chen, Xiaohong, et al.
Publicado: (2019)

Cognitive impairment in NMOSD—More questions than answers
por: Czarnecka, Dominika, et al.
Publicado: (2020)

NMOSD—Diagnostic Dilemmas Leading towards Final Diagnosis
por: Szewczyk, Anna K., et al.
Publicado: (2022)

NMOSD and MOGAD Dual Positivity: An Extremely Rare Phenomenon
por: Agarwal, Ayush, et al.
Publicado: (2022)

Acute liver injury in a Glatopa-treated patient with MS
por: Sabatino, Joseph J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_22i9oo3jptudrmhr29l0kgg5i9